Search Results

< Back to the upcoming events page Registration is closed. Please contact us at events@ncf.net to be added to the waitlist. ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Hear four presentations from neuroendocrine cancer experts. Engage in two Q&A sessions. Listen to a patient story. Learn about liver-directed therapy, systemic therapy, PRRT, and clinical trials. Network with other patients and caregivers. A light dinner will be served. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Alexandra Gangi (Cedar-Sinai Medical Center). This event will not be broadcast or recorded. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> LOCATION Sandbourne Santa Monica 1740 Ocean Avenue Santa Monica, CA 90401 THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 3:45 - 4:15 PM Check-in 4:15 - 4:25 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 4:25 - 4:30 PM Patient Story 4:30 - 4:45 PM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Gabriel Lipshutz, MD, Interventional Radiologist, Cedars-Sinai 4:45 - 5 PM Systemic Therapy for NETs: Medical Options for Metastatic Tumors J. Randolph Hecht, MD, UCLA 5 - 5:45 PM Q&A with Expert Panel Callisia Clarke, MD, Julie Hallet, MD, Gabriel Lipshutz, MD, Randolph Hecht, MD; Moderated by Alexandra Gangi, MD 5:45 - 6:30 PM Break & Dinner 6:30 - 6:45 PM PRRT: Current & New Trends Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 6:45 - 7:00 PM Clinical Trials: The Latest & Greatest Heloisa Soares, MD, Huntsman Cancer Institute 7:00 - 7:30 PM Q&A with Expert Panel Thorvardur Halfdanarson, MD, Heloisa Soares, MD, Alexandra Gangi, MD; Moderated by Andrew Hendifar, MD 7:30 PM Closing Neuroendocrine Cancer Foundation Team This agenda is subject to change. Please check this page for the most updated agenda. ABOUT OUR SPEAKERS Callisia Clarke, MD, MS, FACS, FSSO Chief of MCW Surgery Medical College of Wisconsin Panelist Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Moderator/Panelist Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Thorvardur Halfdanarson, MD Medical Oncologist Mayo Clinic Speaker/Panelist Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is the President Emeritus for the North American Neuroendocrine Tumor Society (NANETS). Julie Hallet, MD, MSc., FRCSC Surgical Oncologist Sunnybrook Health Sciences Center Panelist Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet’s research focuses on health services research to improve the fidelity of care delivery in cancer surgery through patient-centred quality monitoring, high-performing team care models, and patient risk-communication support. Her work has obtained over $10 millions in peer-reviewed operating grants and led to more than 220 peer-reviewed publications. J. Randolph Hecht, MD Medical Oncologist UCLA Health Speaker/Panelist Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center Moderator The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. J. Gabriel Lipshutz, MD Interventional Radiologist Cedars-Sinai Medical Center Speaker/Panelist H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. Dr. Heloisa Soares Medical Oncologist Huntsman Cancer Institute Speaker/Panelist Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79.

<< Go back to the Podcast page EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. MEET DR. GUILLAUME PEGNA Dr. Pegna is a medical oncologist specializing in caring for adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas, as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient and supporting them through their treatment journeys. TOP 10 ABSTRACTS AT THE 2024 NANETS SYMPOSIUM: View the abstracts in the NANETS 2024 Symposium Abstract Guide Improving our understanding of PRRT/optimizing therapy: Mosalem et al. Abstract C-19 Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/ Innumerable Bone Metastases Singh and Iyer et al. Abstract O-13 Prevalence of CHIP Mutations in patients with Neuroendocrine Tumors and Role in Predicting Hematologic Toxicity to PRRT and Chemotherapy Fidelman et al. Abstract C-27 A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases Alpha PRRT is Coming Wahl et al. Abstract C-37 Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs) Strosberg et al. Abstract C-16 Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors Halperin et al. Abstract C-17 ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Phase 1b safety/efficacy Novel Treatments/Treatment Combinations Chauhan et al. Abstract C-5 Once-daily Oral Paltusotine in the Treatment of Patients With Carcinoid Syndrome: Results From a Phase 2, Randomized, Parallel-Group Study D’Souza, Soulen et al. Abstract C-29 Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors Improving Our Understanding of NETs: Basic, Translational, and Epidemiologic Studies of NETs Liu and Yao: Abstract B-1 Development of innovative in vitro and in vivo patient[1]derived cancer models for translational studies in G1/G2 gastroenteropancreatic neuroendocrine tumors Estrada and Bergsland et al. Abstract O-2 Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O'Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., Washington, K., … Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors . CA: a cancer journal for clinicians , 74 (4), 359–367. https://doi.org/10.3322/caac.21840 ABOUT NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the November 21-23, 2024 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here: NANETS Abstract Library 2024 NANETS Abstracts Booklet While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. RESOURCES WATCH Dr. Will Pegna Discusses Highlights from the 2024 NANETS Symposium LISTEN Top 10 Highlights of the 2023 NANETS Symposium Top 10 Highlights of the 2022 NANETS Symposium DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC << Back A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab IDENTIFIER ( ClinicalTrials.gov ) : NCT05142696 DRUG/TREATMENT : LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab PHASE : 1b / 2 STATUS : Recruiting SPONSOR : Novartis Pharmaceuticals DESCRIPTION: Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC ." Recorded: June 20, 2024 This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Novartis Pharmaceuticals EMAIL: novartis.email@novartis.com PHONE: 1-888-669-6682 RELATED RESOURCES : Clinical Trials Using Lutetium Lu 177 Dotatate - NCI "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

< Back to the upcoming events page ABOUT Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. Download Presentation Slides >>> ABOUT MEGHAN LASZLO, MS, RD, CSO Registered Dietitian Board-Certified Specialist in Oncology Nutrition Meghan Laszlo MS, RD, CSO is an oncology dietitian at Cedars-Sinai in Los Angeles, California. For individuals outside of Cedars-Sinai, Meghan Laszlo sees patients through Nourish, a telehealth platform that accepts insurance (Aetna, BCBS, Cigna, United). Insurance for telehealth is available to those residing in Arizona, California, Colorado, Connecticut, Hawaii, Idaho, Indiana, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming! Meghan Laszlo MS, RD, CSO Phone: 424-235-5026 RESOURCES T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Back Peptide Receptor Radionuclide Therapy (PRRT) PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC COMPOSE (GEP-NETs) Alpha PRRT with Pb-212 VMT ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET Alpha PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Combo Trial with Lu177 + Additional Medication Lu177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine in GEP-NETs Lu177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs PRRT for Specific Populations Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients PRRT Comparison Trial of Lu177 versus Another Medication COMPOSE (GEP-NETs) ComPareNET Lu-177 vs CAPTEM in PNETs

<< Go back to the Podcast page EPISODE 33: FOCUS ON TARGETED THERAPIES Download a Transcript of this Episode >>> ABOUT THIS EPISODE What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. MEET DR. SCOTT PAULSON Dr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute. Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachusetts. His fellowship was completed in medical oncology at the University of California, San Francisco. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy. TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs: What are targeted therapies? Are they considered chemotherapy? How do they work? What are the different types of targeted therapies for NETs? When and how are targeted therapies used? What side effects might someone have when taking a targeted therapy? Can targeted therapies affect blood sugars or cause diabetes? Can targeted therapies cause one to be immunocompromised? Can targeted therapies affect one’s blood counts? What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?) How do you decide which targeted therapy to recommend for a patient? Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted? What is your approach with dosing? What is your approach with monitoring? What and how often do people need blood work? Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT? BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies? RESOURCES WATCH March 2024 LACNETS Educational Event with Dr. Jennifer Chan: "TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors" 2023 LACNETS Neuroendocrine Tumor Patient Education Conference with Dr. Pamela Kunz: "The Latest in Systemic Treatments & Considerations for Treatment Sequencing" October 2023: Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib CLINICAL TRIALS MENTIONED IN THIS EPISODE CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the supporters page ABOUT NOVARTIS Novartis is reimagining cancer care with radioligand therapies (RLTs) for patients with advanced cancers, including neuroendocrine tumors. We are proud of our 30-year legacy as an innovator in the neuroendocrine tumor community, leading developments that strive to transform the lives of people with this rare disease. At Novartis, we have a commitment to working together with patients. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine. For more information, please visit: https://us.lutathera.com . This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

<< Back Other Belzutifan/MK-6482 in PNET + PPGL + VHL ENET STUDY: Quality of Life and Well-Being for NET Patients (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors

<< Go back to the Podcast page EPISODE 15: PSYCHO-ONCOLOGY Download a Transcript of this Episode >> ABOUT THIS EPISODE What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole-person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. MEET DR. MONA MOJTAHEDZADEH Mona Mojtahedzadeh, MD, is a psychiatrist at Simms-Mann/UCLA Center for Integrative Oncology , which allows her to continue to perform a work of meaning within a valued population who embrace her into some of their most pivotal moments along their cancer illness trajectory. Dr. Mojtahedzadeh is board certified in Psychiatry as well as in Consultation-Liaison Psychiatry. She obtained her MD from Tehran, Iran’s Shahid Beheshti University of Medical Sciences. She was a general and family practitioner at an underserved health and urgent care clinic in Iran. She completed her psychiatry training through residencies at Texas Tech University Health and Science Center coupled with Loma Linda University Health , where she was granted the department’s research award of the year. She completed a consultation-liaison (C-L) psychiatry fellowship at the University of Southern California and Los Angeles County (LAC+USC) and later served as an Assistant Professor in the Department of Supportive Care Medicine at City of Hope National Medical Center and an Adjunct Assistant Professor of Psychiatry at USC. Her scholarly work includes over 32 publications, posters, and book chapters in areas of medicine, mental health, and their overlap. Learn more about Dr. Mojtahedzadeh and her background here. TOP 10 PSYCHO-ONCOLOGY QUESTIONS 1. Who might seek a psychiatrist? How does one go about finding a psychiatrist that is right for him or her? 2. What is psycho-oncology? If someone living with NET is looking for a psychiatrist, should they seek someone who has trained in psycho-oncology? How does one find such a person? 3. How do you determine if symptoms such as depression, anxiety, mood swing, or fatigue are symptoms caused by their NET cancer or not? 4. Is it safe for NET patients, particularly those with high levels of serotonin, to take antidepressants such as SSRIs that may increase levels of serotonin? 5. If someone living with NET struggles with depression, what is your approach? How do you determine the best treatment option? 6. If someone living with NET struggles with anxiety, how would you approach this patient and how might you manage it? 7. If someone living with NET struggles with sleep issues, what might your thoughts be? 8. What suggestions might you have for loved ones of someone living with cancer who is trying to support someone struggling with depression, anxiety, or mood swings? 9. What suggestions do you have for coping with one’s cancer diagnosis? How might one find some stability and peace during what often feels like a rollercoaster ride? 10. What last words of hope would you leave with the audience? ABOUT PSYCHO-ONCOLOGY "Psycho-oncology is a broad term which encompasses a wide range of psychosocial care to anyone impacted by cancer, whether it is for the individual patient themselves or for their families, loved ones, or caretakers. The idea is to address the breath and soul that may go along with a cancer illness journey. This would ideally incorporate a collaborative work between providers from various disciplines including psychiatrists, psychologists, social workers, oncologists, nurses, palliative care providers, spiritual leaders, nutritionists, and so on who would specialize in the care for cancer, and with a shared mission to improve the well-being and the quality of life of those impacted.” —Mona Mojtahedzadeh, MD PSYCHO-ONCOLOGY RESOURCES Books & Poems The Human Side of Cancer: Living with Hope, Coping with Uncertainty by Jimmie C. Holland, M.D. and Sheldon Lewis On Grief and Grieving: Finding the Meaning of Grief Through the Five Stages of Loss by Elisabeth Kubler-Ross, M.D. & David Kessler Kessler, D. (2019). Finding meaning: The sixth stage of grief. Simon and Schuster When Breath Becomes Air by Paul Kalanithi Man’s Search for Meaning by Viktor Frankl Review Articles Isenberg-Grzeda, E., MacGregor, M., Matsoukas, K., Chow, N., Reidy-Lagunes, D., & Alici, Y. (2020). Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliative & supportive care, 18(5), 602-608. La Salvia, A., Pomeri, A. P., Persano, I., Trevisi, E., Parlagreco, E., Colombi, N., ... & Oliva, F. (2021). Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Comprehensive Psychiatry, 109, 152244 LACNETS Resources Grief Resources >> Caregiver Resources >> Caregiver, Palliative Care and Supportive Care Playlist >> Additional Resources American Psychosocial Oncology Society (APOS) Helpline: (866) 276-7443 apos-society.org Cancer Support Community Helpline: (888) 793-9355 cancersupportcommunity.org American Cancer Society Helpline: (800) 227-2345 Cancer.org DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs << Back ACTION-1 ALPHA PRRT - Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT05477576 DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection COMPARED TO: Everolimus, Sunitinib, Octreotide, Lanreotide PHASE: Phase 3 STATUS: Recruiting April 2023 SPONSOR: RayzeBio, Inc. Dr. Heloisa Soares discusses the ACTION-1 Trial Dr. Will Pegna discusses the ACTION-1 Trial Starting at 5:07 DESCRIPTION: RayzeBio is sponsoring the ACTION-1 study, a phase 3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. Update - Aug 22, 2023 2023 ESMO Abstract shows preliminary safety and efficacy (Note: The meaning of efficacy in clinical trials refers to the capacity of a treatment, device, or medication, to produce a desired effect on the patient population.) Download the PDF here: 1198P-RYZ101-301-ESMO-2023-poster-UPLOAD .pdf Download PDF • 4.57MB For more information on eligibility criteria, trial locations, study details, etc ., go to ClinicalTrials.gov to view this trial here. OTHER HELPFUL RESOURCES: 'Alpha Radioligand Therapy in Neuroendocrine Neoplasms: Current Landscape and Spotlight on RYZ101' CONTACT: RayzeBio Clinical Trials EMAIL: clinicaltrials@rayzebio.com PHONE: 619-657-0057

< Back to the supporters page Defeating cancer with radiopharmaceutical medicines Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. Radiation therapy is a proven approach to treating many cancers and is typically administered by an external beam of high energy rays. In contrast, radiopharmaceuticals selectively deliver radioisotopes to tumors via the bloodstream. Radiopharmaceuticals have the unique advantage of being both diagnostic and therapeutic. The same drug conjugate could be used for both diagnostic imaging and therapeutic use by switching out the radioisotope. Direct visualization of drug conjugate uptake by tumors with imaging allows for proper patient selection to receive the therapeutic radioisotope (e.g. Actinium-225). RayzeBio is sponsoring the phase 1/3 ACTION-1 study for patients who have inoperable, progressive, somatostatin receptor positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NET). The trial is a part of larger international study and will compare the standard of care therapy with 225Ac-DOTATATE (RYZ101). The phase 1 portion of the study will look at the safety and tolerability of RYZ101. The phase 1 of the study is currently enrolling at sites across the country. Main Eligibility Criteria: Over 18 years of age Grade 1-2 well differentiated GEP-NET (GI or pancreas) Ki67 <= 20% Progressive GEP-NET following 2 to 4 cycles of treatment with 177Lu-DOTATATE / 177Lu-DOTATOC. If 177Lu-DOTATATE or 177Lu-DOTATOC treatment was stopped before completing 4 cycles, it should not have been stopped early due to disease progression. Must have had some response to PRRT, defined as tumor shrinkage or tumor stability, that lasted at least 3 months following the last dose of prior 177Lu-DOTATATE/DOTATOC No prior treatment with alkylating agents No prior use of anticancer agents within the following intervals prior to the first dose of study drug: Peptide Receptor Radionuclide Therapy (PRRT): within <8 weeks Chemotherapy: within <6 weeks Small molecule inhibitors: within <4 weeks Biological agents: within <7 days or <5 half-lives No prior external radiation therapy, including stereotactic body radiation therapy (SBRT) No prior radioembolization treatment No significant cardiovascular disease No known brain metastases If you are interested in learning more, please ask your doctor to contact clinicaltrials@rayzebio.com . SITES CURRENTLY ENROLLING: Samuel Mehr, MD Nebraska Cancer Specialists Omaha, NE SMehr@NebraskaCancer.com Michael Morris, MD, MS Advanced Molecular Imaging and Therapy Glen Burnie, MD morrism@amit.health Daneng Li, MD City of Hope Duarte, CA danli@coh.org For more information, contact ClinicalTrials@rayzebio.com. This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

< Back to the upcoming events page LACNETS is hosting an in-person NET Educational Event for patients and caregivers in Minneapolis, Minnesota on Saturday, September 21st from 1:30-5:00 PM. Join us for an afternoon of NET information, connecting and networking. This program has been uniquely designed to maximize the opportunity to engage with NET specialists with two Q&A sessions. LOCATION W Minneapolis - The Foshay 821 S Marquette Ave, Minneapolis, MN 55402 For patients attending the LACNETS in-person NET Educational Event on Saturday, September 21st at the W Minneapolis – The Foshay, parking is available on-site. Please park with valet upon arrival and visit the registration desk to receive your parking validation ticket. At the time of departure, simply hand your validation ticket to the valet for complimentary parking. AGENDA Time Topic Speaker 1:30 - 2 PM Registration 2 - 2:10 PM Welcome LACNETS Team 2:10 - 2:55 PM Patient Panel with 4 NET patients Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS 2:55 - 3:45 PM Q&A with NET Experts Chandrikha Chandrasekharan, MBBS, Medical Oncologist, University of Iowa Philip Boudreaux, MD, FACS, Surgical Oncologist, Louisiana State University 3:45 - 4 PM Break 4 - 4:20 PM Overview of Treatments Emil Lou, MD, Medical Oncologist, University of Minnesota 4:20 - 4:40 PM Sequencing of Treatments Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 4:40 - 5 PM Q&A with a NET Expert Panel Emil Lou, MD, Medical Oncologist, University of Minnesota Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic Patrick McGarrah, MD, Medical Oncologist, Mayo Clinic Ajay Prakash, MD, Medical Oncologist, University of Minnesota Donna D'souza, MD, Interventional Oncologist, University of Minnesota Philip Boudreaux, MD, Surgeon, Louisiana State University Moderated by Lisa Yen, Patient Advocate & Caregiver, LACNETS The North American Neuroendocrine Tumor Society (NANETS) is hosting their Regional NET Education Event for medical providers. Help raise awareness and knowledge of neuroendocrine cancer in the medical community by telling your local healthcare professionals to attend the NANETS Regional NET Education Event on Saturday, September 21st. This event will not be broadcast or recorded. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis” from our 2024 LACNETS Patient Conference . SPEAKERS: Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Thorvardur R. Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). Emil Lou, MD, PhD, FACP Medical Oncology, University of Minnesota Emil Lou, MD, PhD, FACP, is a medical oncologist and neuro-oncologist who provides adult patients with cancer care and treatment through chemotherapy, targeted therapy, and other tailored treatments. In addition to expertise in neuroendocrine tumors, he also specializes in helping patients with gastrointestinal cancers, paraneoplastic disorders, and solid tumor metastases to the brain. He sees patients at the University of Minnesota's Masonic Cancer Clinic at the main campus in Minneapolis. Dr. Lou is also a Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota Medical School. J. Philip Boudreaux, MD, FACS Surgical Oncologist, Louisiana State University J. Philip Boudreaux, MD, FACS, has been recognized for his outstanding contributions to the medical field. He is currently the Professor of Surgery at Louisiana State University Health Sciences Center School of Medicine in New Orleans, LA. Dr. Boudreaux educates medical students and provides high-quality care to patients. While he has held that role for over 20 years, he has spent the last 38 years expanding his knowledge and skills in liver, pancreas, kidney transplantation, organ donation, hepatobiliary and pancreatic surgery, radio frequency ablation of liver tumors, neuroendocrine tumors and carcinoids. His most recent new treatment for metastatic hepatic tumors includes Histotripsy, the destruction of tumor non-invasively with ultrasound. Dr. Boudreaux instituted the liver and pancreas transplant programs at LSU, performed the first pancreas transplant in Louisiana, and initiated the liver and kidney transplant programs at Children’s Hospital, New Orleans. He served as the Director of Liver/Pancreas/Kidney Transplant Services at LSU and Children’s Hospital pre-Katrina. Dr. Boudreaux has spoken publicly at a variety of conferences and educated residents regarding transplant and other related topics. He has published over 75 peer-reviewed publications. Dr. Boudreaux has operated upon over 2,000 patients with neuroendocrine tumors. His center continues to innovate, do research, and often finds ways to turn “inoperable” into “opportunity”. His patients enjoy some of the highest long term survival rates reported in the world’s literature to date. The NOLANETS program has expanded to include East Jefferson Hospital in partnership with the Louisiana Children’s Hospital Medical Network hospitals and the Joe Yenni Cancer Center. In his free time, Dr. Boudreaux enjoys sailing, playing music, fishing, hunting, amateur radio (call sign W5AY), and teaching. He has been a member of the Military Auxiliary Radio System (MARS) since 1968. He attributes his achievements to his education and his work ethic instilled by his parents and mentors. Patrick McGarrah, M.D. Medical Oncologist, Mayo Clinic Dr. Patrick W. McGarrah is a medical oncologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. Dr. McGarrah specializes in head and neck, neuroendocrine, and gastrointestinal cancers. He received his medical degree from University of Minnesota Medical School and completed his training in 2023. Dr. McGarrah has expertise in treating neuroendocrine tumors, with special interest in poorly differentiated neuroendocrine carcinoma and NETs of the head and neck. Ajay Prakash, MD, PhD Medical Oncologist, University of Minnesota Dr. Ajay Prakash is a medical oncologist specializing in gastrointestinal malignancies. His research is focused on understanding the relationship between the tumor microenvironment, prognosis, and treatment response, with a specific focus on the role of the microbiome in this process. A better understanding of the microbiome, the community of organisms that reside in most human tissues, may allow us to better tailor treatments and offer patient specific guidance on cancer prevention. Clinically, Dr. Prakash is committed to healthcare equity and the delivery of high-quality, academic medicine to historically underserved communities. Donna D'souza, MD Interventional Radiologist, University of Minnesota Donna D’Souza MD, FSIR is an Associate Professor of Radiology and Interventional Radiologist at theUniversity of Minnesota, as well as the Interventional Radiology Medical Student Clerkship Director at the University of Minnesota. Her clinical interests are interventional oncology (especially treating cancers in the liver), portal hypertension interventions, thyroid interventions and women’s health. Dr D’Souza was born and raised in Australia. She completed her medical school at Monash University, and her Radiology Residency and Master of Medicine degree at University of Melbourne in Australia. She subsequently completed a Vascular and Interventional Radiology fellowship at the University of Toronto, followed by Interventional Radiology and Body Radiology fellowships at the University of Minnesota. In her free time she enjoys travelling the world with her husband, hiking, yoga, learning and speaking Japanese, indoor gardening, and spending time with her two dogs. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. REGISTER